The phase III “eVOLVE-Lung02” is an ongoing study investigating its effectiveness in 1 L advanced PD-L1-positive NSCLC patients in combination with platinum-based systemic chemotherapy [112]. Here, CD274 is linked to non-small cell lung carcinoma.